The augmented potency prompted us to further investigate the combination in a panel of MCL patient primary samples, including treatment-naïve, ibrutinib- or venetoclax-sensitive, and the BTKi- and/or venetoclax-resistant samples (Fig. 4A, Table S2). The gene discussed is IBTK; the disease is mantle cell lymphoma.